Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
Candidiasis, Oral, HIV Infections
About this trial
This is an interventional treatment trial for Candidiasis, Oral focused on measuring AIDS-Related Opportunistic Infections, Fluconazole, Administration, Oral, Antifungal Agents, Candidiasis, Oral, Pharyngeal Diseases, posaconazole
Eligibility Criteria
Inclusion Criteria You may be eligible for this study if you: Are at least 18 years old. Are HIV-positive. Have thrush (oropharyngeal candidiasis). Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms). Are able to take study medication and return for clinic visits during the study. Are expected to live for at least 2 months. Exclusion Criteria You will not be eligible for this study if you: Have received protease inhibitors for the first time within 30 days prior to study entry. Have received certain medications. Have certain other types of fungal infections. Have certain types of cancer. Have received SCH 56592 within 3 months prior to study entry. Are pregnant or breast-feeding. Cannot take medications by mouth. Are allergic to azole drugs. Have certain medical conditions. Have been in this study before.
Sites / Locations
- East Bay AIDS Ctr
- ViRx Inc
- Kaiser Foundation Hospital
- Infectious Disease and AIDS Clinic
- Dupont Circle Physicians Group
- Boulevard Comprehensive Care Ctr
- Miami Veterans Administration Med Ctr
- TRIAD Health Practice
- Community Hosp Indianapolis
- Wayne State Univ / Harper Hosp
- UMDNJ - New Jersey Med School / Cooper Hosp
- Jersey City Med Ctr
- SUNY / Health Science Ctr at Brooklyn
- Univ of Pennsylvania School of Dental Medicine
- Med Univ of South Carolina
- Amelia Ct Clinic
- Univ of Texas Health Sciences Ctr
- Queen Elizabeth Hosp Respiratory Unit